파머징(Pharmerging) 시장 : 성장, 전망, 경쟁 분석(2024-2032년)

The pharmerging market refers to pharmaceutical markets in emerging economies that are expected to grow rapidly and play an increasingly significant role in the global pharmaceutical industry. These markets are characterized by their large populations, rising middle class, improving healthcare infrastructure, and increasing access to medical care, which collectively drive the demand for pharmaceutical products. The pharmerging market is expected to grow at 11.5% by 2032. A brief overview of the pharmerging market highlights several key factors influencing its growth. First, economic development in these countries leads to higher disposable incomes and greater health awareness, contributing to a higher demand for healthcare services and products. Second, governments in these regions are making significant investments in healthcare infrastructure, including hospitals and clinics, which increases accessibility to a wider range of medical treatments. Additionally, regulatory reforms and supportive government policies aimed at encouraging local production of pharmaceuticals stimulate the growth of domestic companies and attract foreign investment. Finally, the increasing prevalence of chronic diseases, coupled with a burgeoning population, underscores the need for expanded healthcare services and pharmaceutical products.

Economic Growth and Increased Healthcare Spending

One of the primary drivers of the pharmerging market is the robust economic growth observed in emerging economies, which has led to increased healthcare spending. As countries like China, India, and Brazil experience GDP growth, there is a corresponding rise in disposable incomes and living standards. This economic prosperity allows more people to afford healthcare services and pharmaceuticals. Government policies in these countries further support this trend by increasing healthcare budget allocations, aiming to provide universal health coverage and improve healthcare infrastructure. This surge in healthcare investment not only boosts the availability of medical treatments but also enhances the overall health awareness among the populace, leading to increased demand for pharmaceutical products.

Expansion of Healthcare Infrastructure

A significant opportunity within the pharmerging market lies in the expansion of healthcare infrastructure. Emerging economies are rapidly building hospitals, clinics, and distribution networks to make healthcare more accessible to their growing populations. This expansion is not limited to urban areas but extends to rural regions, which historically have been underserved. The increase in healthcare facilities necessitates a corresponding increase in pharmaceutical supplies, creating substantial opportunities for pharmaceutical companies to penetrate new markets and establish robust distribution channels.

Regulatory Heterogeneity

Regulatory heterogeneity serves as a key restraint in the pharmerging market. Emerging markets often have diverse and evolving regulatory frameworks that can vary significantly from one country to another. This variability can pose challenges for pharmaceutical companies looking to launch products simultaneously in multiple markets. Navigating these different regulatory environments requires significant resources and expertise, which can delay product launches and increase the cost of market entry.

Competition with Local Manufacturers

A major challenge in the pharmerging market is the competition posed by local pharmaceutical manufacturers. These local companies often have a better understanding of the regional market dynamics and regulatory nuances. They also benefit from established relationships within local healthcare systems and may be viewed more favorably by local consumers. Additionally, local manufacturers can often produce pharmaceuticals at a lower cost due to cheaper labor and materials, making it difficult for international companies to compete on price. This intense competition requires multinational pharmaceutical companies to innovate in terms of product offerings, market strategies, and pricing models to gain a foothold and expand their presence in these regions.

Market Segmentation by Product

In the pharmerging market, segmentation by product reveals that Pharmaceuticals and Healthcare are two significant categories. Pharmaceuticals consistently drive the highest revenue due to the persistent need for medications, driven by an increasing burden of diseases and expanding healthcare access in emerging markets. This segment benefits from both the widespread chronic conditions requiring ongoing pharmaceutical interventions and the acute treatments needed for communicable diseases. On the other hand, the Healthcare segment, encompassing services, healthcare IT, and medical equipment, is projected to experience the highest Compound Annual Growth Rate (CAGR). This surge is fueled by governmental efforts to improve healthcare infrastructure, increasing private investments in hospital facilities, and a growing emphasis on telemedicine and digital health solutions in response to the global push for more efficient healthcare delivery systems.

Market Segmentation by Indication

Market segmentation by indication includes Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, and others. The segment for Cancer and Autoimmune Diseases is expected to witness the highest revenue, largely due to the high cost of treatments and ongoing pharmaceutical innovation aimed at these complex conditions. Additionally, the increasing prevalence of these diseases in emerging markets as populations age and adopt more Western lifestyles contributes to this trend. Conversely, the segment dealing with Lifestyle Diseases such as diabetes and hypertension is anticipated to register the highest CAGR. This growth is primarily driven by the rapid increase in these conditions among populations in emerging markets, spurred by changing diets, increasing urbanization, and more sedentary lifestyles.

Market Segmentation by Distribution Channel

Regarding the market segmentation by distribution channel, Hospitals and Retail Pharmacies are key players. Hospitals account for the highest revenue within this segment, as they are the primary health service delivery points offering both inpatient and outpatient care. The comprehensive care requirements and the need for specialized pharmaceuticals fuel their dominant revenue position. Retail Pharmacies are projected to see the highest CAGR, attributed to the growing trend of self-medication, increased accessibility, and the expansion of pharmacy networks across urban and rural areas. Moreover, the rising confidence in pharmaceutical retail through chain pharmacies and the growing acceptance of generic drugs play crucial roles in this growth. Additionally, e-commerce channels are rapidly gaining traction due to the convenience of online ordering and the increasing penetration of internet services, indicating a potential shift in consumer behavior in the pharmaceutical distribution landscape in emerging markets.

Regional Insights

In the pharmerging market, geographic trends highlight significant growth across various regions, with Asia-Pacific leading in terms of both the highest Compound Annual Growth Rate (CAGR) and revenue generation. In 2023, countries like China and India dominated the market revenue due to their large populations, increasing healthcare expenditure, and expanding pharmaceutical manufacturing capabilities. These nations have become hubs for pharmaceutical innovation and production, driven by supportive government policies and a rising middle class. Looking forward to the forecast period of 2024 to 2032, Asia-Pacific is expected to maintain its lead in growth rates due to ongoing urbanization, healthcare infrastructure improvements, and the increasing prevalence of chronic diseases. Latin America and Eastern Europe are also expected to witness notable growth, driven by similar trends of healthcare reforms and economic development, though their overall market share remains smaller compared to Asia-Pacific.

Competitive Trends

In terms of competitive trends, the pharmerging market is characterized by a mix of intense competition among leading pharmaceutical companies and dynamic entries by new regional players. In 2023, top players like Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc, Lupin, Tata Consultancy Services Ltd., Sun Pharmaceutical Industries Ltd., Huadong Medicine Co., Ltd. showcased substantial revenues by leveraging their extensive product portfolios and robust distribution networks. These companies focused on strategic alliances, mergers, and acquisitions to consolidate their market positions, while also investing heavily in research and development to innovate new treatments for complex diseases. Looking into the forecast period of 2024 to 2032, these companies are expected to continue their emphasis on expanding into untapped markets, particularly focusing on generic drugs and biologics, which are anticipated to offer substantial growth opportunities. Additionally, local manufacturers in regions such as India and China are expected to strengthen their market presence by capitalizing on cost advantages and local regulatory support, thereby intensifying the competitive landscape. These trends are poised to define the strategic directions of the pharmerging market, with companies constantly adapting to the evolving healthcare demands and regulatory environments in these dynamic regions.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Pharmerging market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Pharmerging market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Product

• Pharmaceuticals

Branded Prescription Drugs

Generic Drugs

Branded Generics

Unbranded Generics

OTC Drugs

• Healthcare

Medical Devices

Diagnostic Instruments

Others (IT and Record Management)

Indication

• Lifestyle Diseases
• Cancer and Autoimmune Diseases
• Infectious Diseases
• Others

Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• E-commerce
• Drugs Stores

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Pharmerging market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Pharmerging market?

Which is the largest regional market for Pharmerging market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Pharmerging market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmerging market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Pharmerging Market
• 2.2. Global Pharmerging Market, By Product, 2023 (US$ Million)
• 2.3. Global Pharmerging Market, By Indication, 2023 (US$ Million)
• 2.4. Global Pharmerging Market, By Distribution Channel, 2023 (US$ Million)
• 2.5. Global Pharmerging Market, By Geography, 2023 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2023

3. Pharmerging Market: Competitive Analysis

• 3.1. Market Positioning of Key Pharmerging Market Vendors
• 3.2. Strategies Adopted by Pharmerging Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2023 Versus 2032

4. Pharmerging Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Pharmerging Market Value, 2022 - 2032, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis
• 4.6. Porter's Five Force Model
  • 4.6.1. Supplier Power
  • 4.6.2. Buyer Power
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Competitive Rivalry
• 4.7. PESTEL Analysis
  • 4.7.1. Political Landscape
  • 4.7.2. Economic Landscape
  • 4.7.3. Technology Landscape
  • 4.7.4. Legal Landscape
  • 4.7.5. Social Landscape

5. Pharmerging Market: By Product, 2022-2032, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2023 Versus 2032
• 5.3. Market Segmentation
  • 5.3.1. Pharmaceuticals
    • 5.3.1.1. Branded Prescription Drugs
    • 5.3.1.2. Generic Drugs
      • 5.3.1.2.1. Branded Generics
      • 5.3.1.2.2. Unbranded Generics
    • 5.3.1.3. OTC Drugs
  • 5.3.2. Healthcare
    • 5.3.2.1. Medical Devices
    • 5.3.2.2. Diagnostic Instruments
    • 5.3.2.3. Others (IT and Record Management)

6. Pharmerging Market: By Indication, 2022-2032, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2023 Versus 2032
• 6.3. Market Segmentation
  • 6.3.1. Lifestyle Diseases
  • 6.3.2. Cancer and Autoimmune Diseases
  • 6.3.3. Infectious Diseases
  • 6.3.4. Others

7. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2023 Versus 2032
• 7.3. Market Segmentation
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Retail Pharmacies
  • 7.3.4. E-commerce
  • 7.3.5. Drugs Stores

8. North America Pharmerging Market, 2022-2032, USD (Million)

• 8.1. Market Overview
• 8.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 8.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 8.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 8.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 8.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 8.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 8.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 8.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 8.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 8.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

9. UK and European Union Pharmerging Market, 2022-2032, USD (Million)

• 9.1. Market Overview
• 9.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 9.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 9.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 9.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.4.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.4.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.5.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.5.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.6.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.6.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

10. Asia Pacific Pharmerging Market, 2022-2032, USD (Million)

• 10.1. Market Overview
• 10.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 10.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 10.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 10.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.4.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.4.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.5.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.5.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.6.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.6.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

11. Latin America Pharmerging Market, 2022-2032, USD (Million)

• 11.1. Market Overview
• 11.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 11.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 11.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 11.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 11.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 11.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 11.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 11.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 11.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 11.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

12. Middle East and Africa Pharmerging Market, 2022-2032, USD (Million)

• 12.1. Market Overview
• 12.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 12.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 12.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 12.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 12.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 12.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 12.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 12.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 12.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 12.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

13. Company Profile

• 13.1. Abbott Laboratories
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. Koninklijke Philips N.V.
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. F. Hoffmann-La Roche Ltd.
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Merck & Co., Inc.
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. Novartis AG
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Johnson & Johnson
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. Teva Pharmaceutical Industries Ltd.
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. AstraZeneca
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. GlaxoSmithKline plc
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives
• 13.10. Lupin
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Portfolio
  • 13.10.4. Strategic Initiatives
• 13.11. Tata Consultancy Services Ltd.
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Portfolio
  • 13.11.4. Strategic Initiatives
• 13.12. Sun Pharmaceutical Industries Ltd.
  • 13.12.1. Company Overview
  • 13.12.2. Financial Performance
  • 13.12.3. Product Portfolio
  • 13.12.4. Strategic Initiatives
• 13.13. Huadong Medicine Co., Ltd.
  • 13.13.1. Company Overview
  • 13.13.2. Financial Performance
  • 13.13.3. Product Portfolio
  • 13.13.4. Strategic Initiatives
• 13.14. Other Notable Players
  • 13.14.1. Company Overview
  • 13.14.2. Financial Performance
  • 13.14.3. Product Portfolio
  • 13.14.4. Strategic Initiatives